Lausanne based Debiopharm Innovation Fund Launches $150 million Seed Funding Initiative. It plans to deploy additional capital to support up to 15 seed-stage startups each year. Building on its strong track record of investing in 25 companies since the inception of the fund in 2006, with a focus on Digital Health since 2017.
The fund will now add seed funding activity to invest in more companies even earlier, with the ambition to transform pharmaceutical research and development (R&D) and advance digital innovation in cancer care.
co-founder and CEO at Neuroute. “We are on track to make monumental progress in developing AI for clinical trials, which will enable transformative medicines to be brought to patients more effectively and efficiently.”
These are inspiring times for novel ideas to come to life, as new disruptive AI models reveal fresh insights from complex data and dramatically accelerate the application of research learning into future standards of care.
co-founder and CEO at Tune Insight. “The potential of predictive AI models for precision medicine is tremendous, and our solution can help train these data-hungry models without ever compromising on data privacy and security.”
His is where our strategic funding and guidance can be the springboard for startups on their path to growth, positioning Debiopharm at the forefront of the innovation stage globally. Debiopharm plans to support the most successful startups through their subsequent Series A financing, which will remain the fund’s flagship activity.
Marc Cikes, Managing Director of Debiopharm Innovation Fund. “We envision patient-centric clinical trials, with more patients able to access novel treatments earlier. Last, we imagine the emergence of AI-powered care, enabling earlier diagnosis, more precise prognosis, and truly individualized treatment pathways.”
Investments will focus on the next generation of pharma R&D to accelerate drug development, on new technology solutions enabling a more patient-centric approach in clinical trials, and on digital platforms uncovering new insights from clinical data for more personalized care pathways.
About Debiopharm Innovation Fund
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides funding and guidance for companies with an ambition to improve the patient journey and transform pharmaceutical R&D. Since 2017 Debiopharm has invested in 15 AI and digital health companies, typically leading the investment rounds. As As of September 2023, Debiopharm Innovation fund is expanding its footprint through a new Seed financing activity.